Lipoxins and epoxyeicosatrienoic acids: Potential for inhibitors of soluble epoxide hydrolase in severe asthma?

American Journal of Respiratory and Critical Care Medicine

Volumn 190, Issue 8, 2014, Pages 848-849

  Chung, Kian Fan ^a,b  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ACTIVATED POTASSIUM CHANNEL; CYTOCHROME P450; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEUKOTRIENE A4; LIPOXIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; LIPOXIN A;

AIRWAY SMOOTH MUSCLE CELL; ARACHIDONIC ACID METABOLISM; ASTHMA; DISEASE SEVERITY; EDITORIAL; ENDOPLASMIC RETICULUM; HUMAN; HYPERPOLARIZATION; LEUKOCYTE AGGREGATION; LUNG LAVAGE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; THROMBOCYTE AGGREGATION; FEMALE; MALE; METABOLISM;

ASTHMA; EPOXIDE HYDROLASES; FEMALE; HUMANS; LIPOXINS; MALE; OXIDATIVE STRESS;

EID: 84922021676     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201409-1659ed     Document Type: Editorial

References (17)

1. Levy BD, Bonnans C, Silverman ES, Palmer LJ, Marigowda G, Israel E; Severe Asthma Research Program, National Heart, Lung, and Blood Institute. Diminished lipoxin biosynthesis in severe asthma. Am J Respir Crit Care Med 2005;172:824-830.
2. 4 generation and lipoxin A4 receptor expression are decreased in severe asthma. Am J Respir Crit Care Med 2008;178:574-582.
3. 4, an endogenous anti-inflammatory compound. J Allergy Clin Immunol 2005;115:55-60.
4. Ono E, Dutile S, Kazani S, Wechsler ME, Yang J, Hammock B, Douda ND, Tabet Y, Khaddaj-Mall R, Sirois M, et al.; National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. Lipoxin generation is related to soluble epoxide hydrolase activity in severe asthma. Am J Respir Crit Care Med 2014;190:886-897.
5. Imig JD. Epoxides and soluble epoxide hydrolase in cardiovascular physiology. Physiol Rev 2012;92:101-130.
6. Morin C, Sirois M, Echave V, Rousseau E. CPI-17 silencing-reduced responsiveness in control and TNF-α-treated human bronchi. Am J Respir Cell Mol Biol 2008;39:638-643.
7. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin DC, Liao JK. Anti-in flammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999;285:1276-1279.
8. Norwood S, Liao J, Hammock BD, Yang GY. Epoxyeicosatrienoic acids and soluble epoxide hydrolase: potential therapeutic targets for inflammation and its induced carcinogenesis. Am J Transl Res 2010;2:447-457.
9. Deng Y, Edin ML, Theken KN, Schuck RN, Flake GP, Kannon MA, DeGraff LM, Lih FB, Foley J, Bradbury JA, et al. Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular in flammatory responses in mice. FASEB J 2011;25:703-713.
10. Morisseau C, Hammock BD. Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health. Annu Rev Pharmacol Toxicol 2013;53:37-58.
11. Lara A, Khatri SB, Wang Z, Comhair SA, Xu W, Dweik RA, Bodine M, Levison BS, Hammel J, Bleecker E, et al.; National Heart, Lung, and Blood Institute's Severe Asthma Research Program. Alterations of the arginine metabolome in asthma. Am J Respir Crit Care Med 2008;178:673-681.
12. Holguin F, Comhair SA, Hazen SL, Powers RW, Khatri SS, Bleecker ER, Busse WW, Calhoun WJ, Castro M, Fitzpatrick AM, et al. An association between L-arginine/asymmetric dimethyl arginine balance, obesity, and the age of asthma onset phenotype. Am J Respir Crit Care Med 2013;187:153-159.
13. 4. Mucosal Immunol 2010;3:270-279.
14. Bhavsar P, Hew M, Khorasani N, Torrego A, Barnes PJ, Adcock I, Chung KF. Relative corticosteroid insensitivity of alveolar macrophages in severe asthma compared with non-severe asthma. Thorax 2008;63:784-790.
15. 4 from alveolar macrophages in severe asthma. Respir Res 2010;11:71.
16. Wang L, Yang J, Guo L, Uyeminami D, Dong H, Hammock BD, Pinkerton KE. Use of a soluble epoxide hydrolase inhibitor in smoke-induced chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2012;46:614-622.
17. Smith KR, Pinkerton KE, Watanabe T, Pedersen TL, Ma SJ, Hammock BD. Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. Proc Natl Acad Sci USA 2005;102:2186-2191.